Filing Analysis
Brainstorm Cell Therapeutics Inc. filed an 8-K to furnish its quarterly financial results for the period ending September 30, 2024 via a press release.
📋 Key Facts
- Report date: November 14, 2024
- Reporting period: Quarter ended September 30, 2024
- The filing includes Exhibit 99.1 containing the full text of the press release regarding financial results.
Brainstorm Cell Therapeutics Inc. has regained compliance with the Nasdaq $1.00 minimum bid price requirement following a 1-for-15 reverse stock split. The company's common stock will continue to trade on the Nasdaq Capital Market.
🚩 Red Flags
- History of non-compliance with Nasdaq minimum bid price requirements (dating back to Nov 2023).
- Execution of a reverse stock split, which is often viewed negatively by the market and can be a sign of distress.
- The company remains subject to continued compliance with all other Nasdaq listing requirements.
📋 Key Facts
- Nasdaq confirmed on October 29, 2024, that the company has regained compliance with the $1.00 minimum bid price requirement (Rule 5550(a)(2)).
- The company successfully met the requirement by closing above $1.00 for ten consecutive trading days as of October 15, 2024.
- A 1-for-15 reverse stock split was executed on September 30, 2024, to facilitate compliance.
- The company had previously been facing delisting threats since November 2023.
Brainstorm Cell Therapeutics Inc. (BCLI) executed a 1-for-15 reverse stock split effective September 30, 2024. The action was taken to increase the per-share bid price to comply with Nasdaq's Minimum Bid Price Requirement and avoid delisting.
🚩 Red Flags
- Reverse stock split (Red flag escalator)
- Implicit delisting risk: The filing explicitly states the move is to meet Nasdaq's Minimum Bid Price Requirement, indicating the stock was trading below $1.00.
📋 Key Facts
- Reverse stock split ratio: 1-for-15.
- Effective date of reverse split: September 30, 2024, at 11:59 p.m. ET.
- Trading on a split-adjusted basis commenced October 1, 2024.
- New CUSIP number for common stock: 10501E300.
- Authorized shares remain unchanged at 250 million.
- Fractional shares will be paid in cash based on the closing price of the last trading day prior to effectiveness.
Brainstorm Cell Therapeutics, Inc. released a company presentation on October 1, 2024, to provide updates to investors via its website and as an exhibit to this filing.
📋 Key Facts
- The Company released a new company presentation on October 1, 2024.
- The presentation is available in the investor relations section of the Company’s website.
- Information provided under Item 7.01 is furnished but not considered 'filed' for purposes of Section 18 liability.
Brainstorm Cell Therapeutics Inc. has approved a 1-for-15 reverse stock split to be effective on September 30, 2024. The move is intended to address the company's need to regain compliance with Nasdaq minimum bid price requirements.
🚩 Red Flags
- Reverse stock split (often used to avoid delisting due to low share price)
- Explicit mention of the need 'to regain compliance with the minimum bid price requirement'
- Risk factor regarding 'continued listing of the Common Stock on Nasdaq'
📋 Key Facts
- The Board of Directors approved a one-for-fifteen (1:15) reverse stock split on September 23, 2024.
- The split is expected to become effective on September 30, 2024, at 11:59 p.m. ET.
- Shares will begin trading on a split-adjusted basis under the same symbol 'BCLI' on October 1, 2024.
- Every 15 shares of common stock will be converted into one share; fractional shares will be paid out in cash based on the closing price prior to the effective time.
- The action follows stockholder approval from the Annual Meeting held on September 16, 2024.
Brainstorm Cell Therapeutics Inc. held its Annual Meeting of Stockholders where shareholders approved several significant structural changes, including a massive increase in authorized shares and authorization for the Board to execute a reverse stock split.
🚩 Red Flags
- Authorization of a reverse stock split (1-for-5 to 1-for-15) is a classic indicator of potential delisting pressure or efforts to boost share price.
- Significant increase in authorized shares (from 100M to 250M) suggests readiness for large-scale equity dilution.
📋 Key Facts
- Stockholders approved an amendment to increase authorized Common Stock from 100,000,000 to 250,000,000 shares.
- Stockholders approved authorization for the Board to implement a reverse stock split with a ratio between 1-for-5 and 1-for-15 at its discretion on or before September 16, 2025.
- The 2014 Stock Incentive Plan and 2014 Global Share Option Plan were amended to increase the share pool by 8,000,000 shares (totaling 13,600,000) and extend their terms by ten years.
- Ratification of Brightman Almagor Zohar & Co. as independent registered public accounting firm for fiscal year ending Dec 31, 2024.
Brainstorm Cell Therapeutics Inc. filed an 8-K to furnish its quarterly financial results for the period ending June 30, 2024 via a press release.
📋 Key Facts
- The filing is a standard announcement of quarterly earnings (Item 2.02).
- Financial results pertain to the quarter ended June 30, 2024.
- Results were released on August 14, 2024.
Brainstorm Cell Therapeutics Inc. announced the scheduling of its 2024 Annual Meeting of Stockholders, to be held virtually on September 16, 2024. The filing provides updated deadlines for stockholder proposals and director nominations due to the meeting date differing from the previous year's anniversary.
📋 Key Facts
- 2024 Annual Meeting scheduled for Monday, September 16, 2024, at 10:00 a.m. ET.
- The meeting will be held virtually.
- Record date for stockholders entitled to vote is August 12, 2024.
- Deadline for stockholder proposals for inclusion in proxy materials (Rule 14a-8) is August 12, 2024.
- Deadline for director nominations under Rule 14a-19 is August 9, 2024.
Brainstorm Cell Therapeutics Inc. received a deficiency notice from Nasdaq because its Market Value of Listed Securities (MVLS) fell below the required $35 million threshold between June 2, 2024, and July 17, 2024. The company has until January 14, 2025, to regain compliance by maintaining an MVLS of at least $35 million for ten consecutive business days.
🚩 Red Flags
- Delisting notice/Non-compliance with Nasdaq listing rules (Rule 5550(b)(2)).
- Market capitalization has fallen below the required threshold, indicating significant loss in shareholder value or market confidence.
- Risk of delisting if compliance is not met by January 14, 2025.
📋 Key Facts
- Received MVLS Deficiency Notice from Nasdaq on July 18, 2024.
- MVLS was below the required $35 million minimum between June 2, 2024, and July 17, 2024.
- Compliance deadline (Compliance Date) is January 14, 2025.
- To regain compliance, MVLS must close at $35 million or more for a minimum of ten consecutive business days during the compliance period.
Brainstorm Cell Therapeutics Inc. entered into a Securities Purchase Agreement to raise approximately $4.0 million through the sale of common stock, pre-funded warrants, and unregistered warrants at a price of roughly $0.36 per share. The offering includes significant warrant coverage that will lead to substantial future dilution.
🚩 Red Flags
- Significant potential dilution: The issuance of over 16.6 million unregistered warrants represents a massive amount of future common stock relative to current market cap.
- Low share price: The offering price of $0.36 per share is characteristic of highly distressed micro-cap financing.
- Warrant Amendment: Existing warrants from July 2023 were amended as part of this deal, indicating restructuring of debt/equity obligations.
📋 Key Facts
- Gross proceeds from the offering are approximately $4.0 million before fees.
- Securities include 7,918,764 registered shares of common stock and 3,192,347 pre-funded warrants.
- Unregistered warrants were issued to purchase up to 16,666,667 shares of Common Stock.
- Warrants have an exercise price of $0.3912 per share and expire in five years.
- Maxim Group LLC is acting as the exclusive placement agent with a 6.0% cash fee.
- The company will file an S-3 registration statement to register the resale of shares underlying the warrants by December 26, 2024.
Brainstorm Cell Therapeutics announced on June 26, 2024, that it has reached alignment with the FDA regarding Chemistry, Manufacturing, and Controls (CMC) for its Phase 3b clinical trial of NurOwn®, an investigational therapy for ALS.
📋 Key Facts
- Reached alignment with the FDA on CMC aspects for the NurOwn® Phase 3b clinical trial.
- The therapeutic target is amyotrophic lateral sclerosis (ALS).
- Filing date: June 26, 2024.
Brainstorm Cell Therapeutics Inc. announced the appointment of Dr. Hartounian as Executive Vice President and Chief Operating Officer, effective June 24, 2024. The filing details his extensive background in biotechnology leadership and the specific terms of his employment agreement.
🚩 Red Flags
- None identified in this specific filing.
📋 Key Facts
- Dr. Hartounian appointed as EVP and COO, effective June 24, 2024.
- Base annual salary: $450,000.
- Equity compensation includes an option to purchase 60,000 shares of common stock and a one-time grant of 30,000 shares of restricted common stock.
- Option vesting schedule: 25% on the first anniversary; remaining 75% in equal quarterly installments over the following three years.
- Restricted Stock Grant vests in full on the first anniversary of the start date.
- Eligible for an annual cash bonus of up to 35% of base salary and a $10,000 signing bonus.
Brainstorm Cell Therapeutics Inc. has received a temporary exception from Nasdaq, extending its deadline to regain compliance with the $1.00 minimum bid price requirement until October 21, 2024. The company must implement a reverse stock split by October 7, 2024, if it fails to achieve compliance through other means by mid-August 2024.
🚩 Red Flags
- Delisting notice/non-compliance with minimum bid price requirement
- Likely upcoming reverse stock split to avoid delisting
- Ongoing struggle to maintain minimum market price
📋 Key Facts
- Nasdaq granted a temporary exception until October 21, 2024, following an expedited review process.
- The company must regain compliance with the $1.00 minimum bid price requirement (Nasdaq Listing Rule 5550(a)(2)).
- A reverse stock split is anticipated if compliance is not achieved by mid-August 2024 to meet the October 7, 2024 deadline.
- Failure to regain compliance by October 21, 2024, will result in delisting from the Nasdaq Capital Market.
Brainstorm Cell Therapeutics Inc. failed to regain compliance with Nasdaq's $1.00 minimum bid price requirement by the April 29, 2024 deadline. The company has filed an appeal to the Nasdaq Hearings Panel and is participating in an expedited review process to stay delisting.
🚩 Red Flags
- Failure to meet minimum bid price requirement (delisting risk)
- Potential for suspension of securities if appeal is unsuccessful
- Uncertainty regarding the Panel's acceptance of the company's compliance plan
📋 Key Facts
- The company failed to meet the Minimum Bid Price Requirement (Nasdaq Listing Rule 5550(a)(2)) by April 29, 2024.
- On May 2, 2024, the Company submitted a hearing request to the Nasdaq Hearings Panel to appeal the Staff's determination.
- The hearing request has stayed the suspension of securities and the filing of Form 25-NSE pending a final decision.
- The company intends to participate in an expedited review process with the Panel.
- Trading on Nasdaq under symbol 'BCLI' continues in the interim while the appeal is pending.
Brainstorm Cell Therapeutics announced the resignation of Co-CEO Dr. Stacy Lindborg, effective May 9, 2024, and her subsequent appointment to the Board of Directors. Additionally, Dr. Ibrahim B. Dagher has been promoted to Executive Vice President and Chief Medical Officer.
🚩 Red Flags
- Executive turnover (Co-CEO departure) can create leadership instability in micro-cap biotech firms.
- Cash outflow of $300,000 for a separation bonus in a potentially capital-constrained environment.
📋 Key Facts
- Dr. Stacy Lindborg is resigning as Co-CEO effective May 9, 2024; she will transition to a non-employee Director role on the same date.
- The company will pay Dr. Lindborg a $300,000 lump sum separation bonus by March 15, 2025.
- Dr. Lindborg's unvested equity awards (except for a specific March 11, 2024 RSA grant) will be forfeited upon her departure from the executive role.
- The March 11, 2024 RSA grant of 241,935 shares will continue to vest while she serves on the Board and features an acceleration clause upon a change of control.
- Dr. Ibrahim B. Dagher has been promoted from Chief Development Officer to Executive Vice President and Chief Medical Officer.
- The company stated Dr. Lindborg's resignation is not due to any disagreement with the Company or its Board.
Brainstorm Cell Therapeutics Inc. has regained compliance with the Nasdaq Minimum Market Value Requirement, resolving a delisting threat initiated in November 2023.
🚩 Red Flags
- Historical delisting risk (though currently resolved)
📋 Key Facts
- On April 10, 2024, Nasdaq notified the Company that it has regained compliance with the Minimum Market Value Requirement under Nasdaq Listing Rule 5550(b)(2).
- The deficiency was originally identified on November 6, 2023, due to market value falling below $35 million.
- The matter regarding the minimum market value requirement is now considered closed by Nasdaq.
Brainstorm Cell Therapeutics announced that the FDA has granted a Special Protocol Assessment (SPA) for the design of its Phase 3b clinical trial of NurOwn® in treating amyotrophic lateral sclerosis (ALS). This represents a significant regulatory milestone for the company's lead product candidate.
📋 Key Facts
- FDA issued written agreement under a Special Protocol Assessment (SPA) on April 9, 2024.
- The SPA pertains to the design of a Phase 3b trial for NurOwn® in amyotrophic lateral sclerosis (ALS).
- Company scheduled a conference call and webcast for April 9, 2024, to discuss the development.
Brainstorm Cell Therapeutics Inc. amended its existing at-the-market (ATM) equity offering program to remove Leerink Partners LLC as an agent.
🚩 Red Flags
- Reduction in number of agents for ATM offering may indicate a shift in brokerage relationships or strategic restructuring of capital raising efforts.
📋 Key Facts
- Amendment No. 1 to the Distribution Agreement was executed on April 2, 2024.
- The original agreement dated August 9, 2021, allows for the sale of common stock up to an aggregate offering price of $100.0 million.
- Leerink Partners LLC has ceased to be an agent under the Distribution Agreement.
- Raymond James & Associates, Inc. remains as an agent in the program.
Brainstorm Cell Therapeutics Inc. filed an 8-K to furnish its annual financial results for the fiscal year ended December 31, 2023 via a press release.
📋 Key Facts
- Report date: April 1, 2024
- Reporting period: Fiscal year ended December 31, 2023
- The filing includes Exhibit 99.1 containing the full text of the earnings press release.
- The company is listed on the NASDAQ Capital Market under ticker BCLI.